Siegfried Reich - 09 Feb 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc.

Role: EVP & Chief Scientific Officer
Signature: /s/ Paolo Tombesi, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 09 Feb 2022
Net transactions value: -$14,411
Form type: 4
Filing time: 11 Feb 2022, 17:10:31 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TPTX	Common Stock	Sale	$14,411	-397	-10%	$36.30	3,448	09 Feb 2022	Direct	F1
transaction	TPTX	Common Stock	Award	$0	+13,567	+393%	$0.000000	17,015	09 Feb 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TPTX	Stock Option (right to buy)	Award	$0	+48,833		$0.000000	48,833	09 Feb 2022	Common Stock	48,833	$37.68	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021.
F2	Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan.
F3	1/48th of the shares vest monthly following February 9, 2022.